Risk of cardiovascular death in elderly patients with possible heart failure. B-type natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population

被引:34
作者
Alehagen, U [1 ]
Lindstedt, G
Levin, LÅ
Dahlström, U
机构
[1] Linkoping Univ Hosp, Dept Cardiol, Linkoping, Sweden
[2] Univ Gothenburg, Sahlgren Acad, Gothenburg, Sweden
[3] Ctr Med Technol Assessment, Linkoping, Sweden
关键词
natriuretic peptides; elderly population; heart failure; prognosis;
D O I
10.1016/j.ijcard.2004.10.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure is common in the elderly population and carries a serious prognosis. We evaluated EDTA-plasma B-type natriuretic peptide (brain natriuretic peptide, BNP) and the aminoterminal fragment of proBNP (N-terminal proBNP) as prognostic markers in elderly primary care patients with symptoms of heart failure. Methods: From 474 patients attending primary care for symptoms of dyspnea, fatigue and/or peripheral edema, blood was sampled in plastic tubes containing EDTA to measure BNP by non-extraction immunoradiometric assay and N-terminal proBNP by non-extraction radioimmunoassay. Patients were evaluated with respect to history and function by NYHA classification and Doppler echocardiography. Follow-up time was 6 years. Cox regression analysis was performed to identify the weight of risk variables. Conclusion: Total 6-year mortality was 20% (102 patients out of 5 10), and cardiovascular (CV) mortality was 14% (71 patients, 70% of total mortality). BNP and N-terminal proBNP were essentially equally useful as prognostic markers. In patients with the highest quartiles of plasma concentration of BNP and N-terminal proBNP, respectively, the risk of cardiovascular mortality was 10 and 4.8 times, respectively, higher than that in those in the lowest quartile. Peptide concentrations varied widely within all functional groups including those with normal echocardiographic findings. Plasma concentrations of BNP and N-terminal proBNP give important prognostic information concerning risk of cardiovascular mortality. Cost-effective "clinical pathways" should be outlined for patients with elevated peptide concentrations. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:125 / 133
页数:9
相关论文
共 48 条
[1]  
Alehagen U., 2002, HeartDrug, V2, P211, DOI 10.1159/000067723
[2]   Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care [J].
Alehagen, U ;
Lindstedt, G ;
Eriksson, H ;
Dahlström, U .
CLINICAL CHEMISTRY, 2003, 49 (08) :1337-1346
[3]  
ALEHAGEN U, 2003, THESIS LINKOPING U L
[4]   BNP test utilization for CHF in community hospital practice [J].
Apple, FS ;
Trinity, E ;
Steen, J ;
Prawer, S ;
Wu, AHB .
CLINICA CHIMICA ACTA, 2003, 328 (1-2) :191-193
[5]   Natriuretic peptides and myocardial ischaemia [J].
Baxter, GF .
BASIC RESEARCH IN CARDIOLOGY, 2004, 99 (02) :90-93
[6]   NT-proBNP and BNP: biomarkers for heart failure management [J].
Bettencourt, P .
EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) :359-363
[7]   B-type natriuretic peptide and ischemia in patients with stable coronary disease - Data from the Heart and Soul Study [J].
Bibbins-Domingo, K ;
Ansari, M ;
Schiller, NB ;
Massie, B ;
Whooley, MA .
CIRCULATION, 2003, 108 (24) :2987-2992
[8]  
Cleland JGF, 1998, LANCET, V352, P1
[9]   Survival of patients with a new diagnosis of heart failure: a population based study [J].
Cowie, MR ;
Wood, DA ;
Coats, AJS ;
Thompson, SG ;
Suresh, V ;
Poole-Wilson, PA ;
Sutton, GC .
HEART, 2000, 83 (05) :505-510
[10]   Clinical applications of B-type natriuretic peptide (BNP) testing [J].
Cowie, MR ;
Jourdain, P ;
Maisel, A ;
Dahlstrom, U ;
Follath, F ;
Isnard, R ;
Luchner, A ;
McDonagh, T ;
Mair, J ;
Nieminen, M ;
Francis, G .
EUROPEAN HEART JOURNAL, 2003, 24 (19) :1710-1718